Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 (Nintedanib) in Bevacizumab-Resistant Ovarian Cancer
NCT01669798Phase 2Completed
- Start
- Feb 2013
- Primary completion
- Sep 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC). Started Feb 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01669798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669798.